Merck & Co. Inc. received FDA clearance of its nine-valent HPV vaccine, Gardasil 9, on Dec. 10, but it’s unclear whether the additional HPV protection offered by the vaccine can help the company and the Center for Disease Control and Prevention overcome the hurdles to widespread vaccination, many of which may be cultural, not scientific.
Gardasil 9 covers five more human papillomavirus types (31, 33, 45, 52 and 58) than Merck’s original Gardasil vaccine approved in 2006 Also see "Gardasil Clears FDA, But Dosing May Pose Administrative Challenges" - Pink